| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgery, Plastic | 9 | 2022 | 111 | 2.750 |
Why?
|
| Melanoma | 10 | 2023 | 944 | 2.350 |
Why?
|
| Dermatology | 4 | 2023 | 34 | 2.300 |
Why?
|
| Programmed Cell Death 1 Receptor | 6 | 2021 | 128 | 2.290 |
Why?
|
| B7-H1 Antigen | 3 | 2020 | 120 | 1.900 |
Why?
|
| Internship and Residency | 5 | 2021 | 1186 | 1.690 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2023 | 115 | 1.580 |
Why?
|
| Eyelid Diseases | 16 | 2005 | 72 | 1.530 |
Why?
|
| Orbital Diseases | 16 | 2016 | 91 | 1.380 |
Why?
|
| Surgeons | 4 | 2022 | 257 | 1.270 |
Why?
|
| Anesthetics, Local | 5 | 2021 | 83 | 1.250 |
Why?
|
| Anesthesia, Local | 5 | 2020 | 47 | 1.220 |
Why?
|
| Eyelids | 15 | 2003 | 119 | 1.160 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 862 | 1.040 |
Why?
|
| Orbit | 18 | 2021 | 102 | 0.980 |
Why?
|
| Dacryocystorhinostomy | 8 | 2003 | 27 | 0.750 |
Why?
|
| Leadership | 2 | 2020 | 230 | 0.720 |
Why?
|
| Pain, Procedural | 1 | 2020 | 8 | 0.710 |
Why?
|
| Hepatitis | 1 | 2021 | 57 | 0.690 |
Why?
|
| Benchmarking | 1 | 2021 | 137 | 0.670 |
Why?
|
| Mohs Surgery | 1 | 2020 | 38 | 0.670 |
Why?
|
| Trigger Finger Disorder | 1 | 2019 | 2 | 0.660 |
Why?
|
| Practice Management, Medical | 1 | 2019 | 12 | 0.650 |
Why?
|
| Humans | 151 | 2023 | 125757 | 0.650 |
Why?
|
| Commerce | 1 | 2019 | 50 | 0.630 |
Why?
|
| Ipilimumab | 5 | 2022 | 63 | 0.620 |
Why?
|
| Lacrimal Apparatus Diseases | 5 | 2004 | 48 | 0.620 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 193 | 0.600 |
Why?
|
| Lacrimal Apparatus | 8 | 2004 | 120 | 0.580 |
Why?
|
| Survivors | 1 | 2020 | 341 | 0.570 |
Why?
|
| Surgical Flaps | 6 | 1999 | 203 | 0.560 |
Why?
|
| Prostheses and Implants | 8 | 2001 | 152 | 0.560 |
Why?
|
| Body Composition | 1 | 2020 | 521 | 0.560 |
Why?
|
| Postoperative Complications | 14 | 2022 | 3080 | 0.540 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2003 | 87 | 0.530 |
Why?
|
| Ethics, Medical | 1 | 2019 | 396 | 0.520 |
Why?
|
| Sclerosing Solutions | 1 | 2016 | 13 | 0.520 |
Why?
|
| Sclerotherapy | 1 | 2016 | 40 | 0.510 |
Why?
|
| Foreign-Body Migration | 4 | 2001 | 72 | 0.490 |
Why?
|
| Conjunctival Diseases | 6 | 1999 | 33 | 0.470 |
Why?
|
| Curriculum | 4 | 2021 | 727 | 0.470 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 616 | 0.470 |
Why?
|
| Skin Diseases | 2 | 2023 | 130 | 0.460 |
Why?
|
| Orbital Implants | 5 | 2000 | 18 | 0.440 |
Why?
|
| Optic Nerve Injuries | 3 | 2014 | 10 | 0.430 |
Why?
|
| Enophthalmos | 6 | 2004 | 15 | 0.430 |
Why?
|
| Suture Techniques | 5 | 2003 | 195 | 0.430 |
Why?
|
| Middle Aged | 49 | 2023 | 27003 | 0.410 |
Why?
|
| Eyelid Neoplasms | 7 | 1998 | 43 | 0.400 |
Why?
|
| Retrospective Studies | 30 | 2023 | 16434 | 0.400 |
Why?
|
| Lidocaine | 3 | 2021 | 46 | 0.380 |
Why?
|
| Blepharoptosis | 4 | 2008 | 67 | 0.370 |
Why?
|
| Skull Base Neoplasms | 2 | 2002 | 36 | 0.370 |
Why?
|
| Immunotherapy | 3 | 2021 | 681 | 0.370 |
Why?
|
| Lacrimal Duct Obstruction | 5 | 2003 | 22 | 0.370 |
Why?
|
| Education, Medical, Graduate | 3 | 2021 | 521 | 0.370 |
Why?
|
| Hyaluronoglucosaminidase | 3 | 2007 | 26 | 0.360 |
Why?
|
| Hyaluronic Acid | 4 | 2007 | 96 | 0.350 |
Why?
|
| Male | 62 | 2023 | 61813 | 0.350 |
Why?
|
| Eye Diseases | 5 | 2007 | 119 | 0.350 |
Why?
|
| Quality of Life | 1 | 2020 | 1952 | 0.350 |
Why?
|
| Female | 75 | 2023 | 67035 | 0.340 |
Why?
|
| Orbital Neoplasms | 5 | 2001 | 65 | 0.340 |
Why?
|
| Ocular Motility Disorders | 2 | 2008 | 38 | 0.340 |
Why?
|
| Neoplasms | 3 | 2020 | 2806 | 0.340 |
Why?
|
| Paranasal Sinus Diseases | 5 | 2004 | 20 | 0.330 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 244 | 0.330 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 3 | 1999 | 46 | 0.330 |
Why?
|
| Conjunctiva | 5 | 1999 | 197 | 0.320 |
Why?
|
| Skin | 3 | 2022 | 519 | 0.320 |
Why?
|
| Sarcoidosis | 3 | 1999 | 60 | 0.310 |
Why?
|
| Blepharospasm | 6 | 2012 | 49 | 0.310 |
Why?
|
| Rhytidoplasty | 2 | 2006 | 10 | 0.300 |
Why?
|
| Skin Transplantation | 4 | 2001 | 60 | 0.300 |
Why?
|
| Granuloma, Foreign-Body | 2 | 2005 | 10 | 0.300 |
Why?
|
| Aged | 35 | 2023 | 19899 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 512 | 0.300 |
Why?
|
| Endoscopy | 4 | 2018 | 281 | 0.290 |
Why?
|
| Blinking | 1 | 2008 | 27 | 0.290 |
Why?
|
| Facial Injuries | 1 | 2007 | 22 | 0.280 |
Why?
|
| Facial Muscles | 7 | 1993 | 33 | 0.280 |
Why?
|
| United States | 6 | 2023 | 10941 | 0.280 |
Why?
|
| Presbyopia | 1 | 2007 | 31 | 0.280 |
Why?
|
| Oculomotor Muscles | 6 | 2008 | 63 | 0.270 |
Why?
|
| Needlestick Injuries | 1 | 2006 | 6 | 0.270 |
Why?
|
| Ectropion | 3 | 2003 | 8 | 0.270 |
Why?
|
| Eye Injuries | 3 | 2006 | 48 | 0.270 |
Why?
|
| Needles | 1 | 2006 | 51 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 24 | 2005 | 2110 | 0.260 |
Why?
|
| Maxillary Sinus | 3 | 2004 | 15 | 0.250 |
Why?
|
| Eye Enucleation | 4 | 2003 | 54 | 0.250 |
Why?
|
| Choristoma | 2 | 2004 | 50 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 1257 | 0.240 |
Why?
|
| Adult | 52 | 2021 | 29760 | 0.240 |
Why?
|
| Skull Base | 2 | 2002 | 53 | 0.240 |
Why?
|
| Facial Dermatoses | 1 | 2005 | 8 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2001 | 668 | 0.240 |
Why?
|
| Ophthalmology | 1 | 2007 | 198 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2002 | 3603 | 0.230 |
Why?
|
| Dermatologic Agents | 1 | 2005 | 31 | 0.230 |
Why?
|
| Immune System Diseases | 2 | 2023 | 47 | 0.230 |
Why?
|
| Laser Therapy | 2 | 1999 | 249 | 0.230 |
Why?
|
| Silicone Elastomers | 3 | 2001 | 35 | 0.230 |
Why?
|
| Blepharoplasty | 3 | 2005 | 22 | 0.220 |
Why?
|
| Durapatite | 3 | 1999 | 17 | 0.220 |
Why?
|
| Polyglactin 910 | 1 | 2003 | 4 | 0.210 |
Why?
|
| Leukocytes | 2 | 2022 | 212 | 0.210 |
Why?
|
| Cost Savings | 1 | 2023 | 71 | 0.210 |
Why?
|
| Microcirculation | 2 | 2021 | 96 | 0.210 |
Why?
|
| Optic Nerve Diseases | 5 | 2000 | 88 | 0.210 |
Why?
|
| Eye Infections, Fungal | 3 | 2001 | 77 | 0.210 |
Why?
|
| Adrenal Insufficiency | 1 | 2023 | 28 | 0.210 |
Why?
|
| Sutures | 1 | 2003 | 65 | 0.200 |
Why?
|
| Natural Language Processing | 1 | 2023 | 62 | 0.200 |
Why?
|
| Polyethylenes | 3 | 1998 | 8 | 0.200 |
Why?
|
| Cohort Studies | 5 | 2023 | 4853 | 0.200 |
Why?
|
| Malpractice | 1 | 2022 | 55 | 0.200 |
Why?
|
| Sinusitis | 2 | 2001 | 116 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2021 | 320 | 0.200 |
Why?
|
| Acute Generalized Exanthematous Pustulosis | 1 | 2022 | 1 | 0.190 |
Why?
|
| Nerve Transfer | 1 | 2022 | 8 | 0.190 |
Why?
|
| Perforator Flap | 1 | 2022 | 9 | 0.190 |
Why?
|
| Craniotomy | 3 | 2001 | 110 | 0.190 |
Why?
|
| Bone Resorption | 2 | 1999 | 42 | 0.190 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2001 | 12 | 0.190 |
Why?
|
| Facial Neoplasms | 1 | 2001 | 19 | 0.190 |
Why?
|
| Mammaplasty | 1 | 2022 | 53 | 0.180 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 3745 | 0.180 |
Why?
|
| Licensure, Medical | 1 | 2021 | 24 | 0.180 |
Why?
|
| Microvessels | 1 | 2021 | 57 | 0.180 |
Why?
|
| Graves Ophthalmopathy | 1 | 2021 | 12 | 0.180 |
Why?
|
| Eye Infections, Bacterial | 2 | 1999 | 92 | 0.180 |
Why?
|
| Pseudotumor Cerebri | 2 | 1999 | 58 | 0.180 |
Why?
|
| Chief Executive Officers, Hospital | 1 | 2020 | 3 | 0.180 |
Why?
|
| Neuralgia | 1 | 2021 | 44 | 0.180 |
Why?
|
| Physician Executives | 1 | 2020 | 40 | 0.170 |
Why?
|
| Carcinoma, Basal Cell | 2 | 1998 | 71 | 0.170 |
Why?
|
| Sexism | 1 | 2020 | 38 | 0.170 |
Why?
|
| Autoimmunity | 1 | 2021 | 172 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 670 | 0.160 |
Why?
|
| Optic Nerve | 5 | 2014 | 114 | 0.160 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1999 | 25 | 0.160 |
Why?
|
| Personnel Management | 1 | 2019 | 7 | 0.160 |
Why?
|
| Intraoperative Complications | 2 | 2018 | 172 | 0.160 |
Why?
|
| Financial Management | 1 | 2019 | 15 | 0.160 |
Why?
|
| GTP Phosphohydrolases | 1 | 2020 | 147 | 0.160 |
Why?
|
| Intubation | 2 | 1989 | 17 | 0.160 |
Why?
|
| Educational Status | 1 | 2020 | 276 | 0.160 |
Why?
|
| Health Care Reform | 1 | 2019 | 51 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 167 | 0.160 |
Why?
|
| Optic Chiasm | 1 | 1999 | 15 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 286 | 0.160 |
Why?
|
| Botulinum Toxins | 3 | 2012 | 121 | 0.150 |
Why?
|
| Exophthalmos | 4 | 1995 | 37 | 0.150 |
Why?
|
| Visual Acuity | 6 | 2014 | 816 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 251 | 0.150 |
Why?
|
| Educational Measurement | 1 | 2021 | 323 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1161 | 0.150 |
Why?
|
| Nutritional Status | 1 | 2020 | 315 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 543 | 0.150 |
Why?
|
| Papilledema | 1 | 1999 | 78 | 0.140 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2018 | 43 | 0.140 |
Why?
|
| Eye Movements | 1 | 1998 | 71 | 0.140 |
Why?
|
| Machine Learning | 1 | 2020 | 251 | 0.140 |
Why?
|
| Time Factors | 7 | 2021 | 6355 | 0.140 |
Why?
|
| Telemedicine | 1 | 2023 | 439 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2014 | 12425 | 0.140 |
Why?
|
| Decompression, Surgical | 2 | 2014 | 96 | 0.140 |
Why?
|
| Follow-Up Studies | 13 | 2023 | 5197 | 0.140 |
Why?
|
| Microscopy, Video | 3 | 2022 | 22 | 0.140 |
Why?
|
| Disease Progression | 2 | 2020 | 2090 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2022 | 3470 | 0.140 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 80 | 0.140 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2012 | 167 | 0.140 |
Why?
|
| Physicians | 1 | 2023 | 589 | 0.130 |
Why?
|
| Cysts | 4 | 1998 | 101 | 0.130 |
Why?
|
| Orbital Fractures | 5 | 2002 | 39 | 0.130 |
Why?
|
| Polyethylene | 3 | 2000 | 15 | 0.130 |
Why?
|
| Iatrogenic Disease | 2 | 1996 | 133 | 0.130 |
Why?
|
| Syndrome | 6 | 2008 | 1121 | 0.130 |
Why?
|
| Abscess | 1 | 1997 | 137 | 0.130 |
Why?
|
| Microsurgery | 1 | 1996 | 69 | 0.130 |
Why?
|
| Diagnosis, Differential | 9 | 2003 | 1902 | 0.130 |
Why?
|
| Surgical Wound Infection | 2 | 1998 | 261 | 0.120 |
Why?
|
| Sclera | 3 | 2000 | 58 | 0.120 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 1314 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3438 | 0.120 |
Why?
|
| Sebaceous Glands | 1 | 1995 | 4 | 0.120 |
Why?
|
| Prosthesis-Related Infections | 1 | 1997 | 179 | 0.120 |
Why?
|
| Methylprednisolone | 2 | 2014 | 93 | 0.120 |
Why?
|
| Neovascularization, Physiologic | 3 | 2000 | 215 | 0.120 |
Why?
|
| Cocaine | 2 | 1994 | 207 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 1998 | 476 | 0.110 |
Why?
|
| Glucocorticoids | 5 | 2022 | 384 | 0.110 |
Why?
|
| Adipose Tissue | 5 | 2000 | 465 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1206 | 0.110 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1993 | 2 | 0.110 |
Why?
|
| Incidence | 1 | 2021 | 3155 | 0.110 |
Why?
|
| Facial Bones | 2 | 1992 | 29 | 0.110 |
Why?
|
| Spasm | 2 | 1990 | 50 | 0.110 |
Why?
|
| Injections, Intralesional | 2 | 2021 | 48 | 0.100 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1993 | 39 | 0.100 |
Why?
|
| Conjunctival Neoplasms | 3 | 1993 | 22 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2020 | 1536 | 0.100 |
Why?
|
| Skull | 2 | 1998 | 141 | 0.100 |
Why?
|
| Zinc Compounds | 1 | 2012 | 7 | 0.100 |
Why?
|
| Skin Aging | 3 | 2012 | 14 | 0.100 |
Why?
|
| 6-Phytase | 1 | 2012 | 3 | 0.100 |
Why?
|
| Nevus | 1 | 1992 | 35 | 0.100 |
Why?
|
| Risk Factors | 3 | 2022 | 10341 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2906 | 0.090 |
Why?
|
| Eyebrows | 2 | 2008 | 13 | 0.090 |
Why?
|
| Osteopetrosis | 1 | 1991 | 14 | 0.090 |
Why?
|
| Child, Preschool | 17 | 2008 | 14137 | 0.090 |
Why?
|
| Amyloidosis | 1 | 1992 | 71 | 0.090 |
Why?
|
| Eye Evisceration | 2 | 2003 | 6 | 0.090 |
Why?
|
| Intraocular Pressure | 4 | 2007 | 144 | 0.090 |
Why?
|
| Biopsy | 4 | 2003 | 1242 | 0.090 |
Why?
|
| Sepharose | 2 | 2000 | 16 | 0.090 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2000 | 44 | 0.090 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 6609 | 0.090 |
Why?
|
| Recurrence | 6 | 2014 | 1421 | 0.090 |
Why?
|
| Neuromuscular Agents | 2 | 2012 | 67 | 0.090 |
Why?
|
| Rosacea | 1 | 1990 | 14 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 2518 | 0.080 |
Why?
|
| Granuloma | 1 | 1990 | 68 | 0.080 |
Why?
|
| Meningeal Neoplasms | 2 | 2008 | 193 | 0.080 |
Why?
|
| Adenoma, Sweat Gland | 1 | 1989 | 4 | 0.080 |
Why?
|
| Sphenoid Bone | 2 | 2000 | 10 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2021 | 8258 | 0.080 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2008 | 19 | 0.080 |
Why?
|
| Muscular Diseases | 1 | 1989 | 103 | 0.080 |
Why?
|
| Adolescent | 17 | 2022 | 19477 | 0.070 |
Why?
|
| Silicones | 1 | 1988 | 37 | 0.070 |
Why?
|
| Meige Syndrome | 1 | 1988 | 9 | 0.070 |
Why?
|
| Edema | 2 | 2005 | 136 | 0.070 |
Why?
|
| Basal Ganglia Diseases | 1 | 1988 | 27 | 0.070 |
Why?
|
| Accommodation, Ocular | 1 | 2007 | 17 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 121 | 0.070 |
Why?
|
| Microphthalmos | 1 | 1987 | 60 | 0.070 |
Why?
|
| Pressure | 2 | 1999 | 131 | 0.070 |
Why?
|
| Eye Abnormalities | 2 | 2001 | 104 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 734 | 0.070 |
Why?
|
| Mutation | 1 | 2020 | 5909 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2021 | 1636 | 0.060 |
Why?
|
| Microscopy, Electron | 6 | 1997 | 396 | 0.060 |
Why?
|
| Coloboma | 2 | 1998 | 45 | 0.060 |
Why?
|
| Muscle, Skeletal | 3 | 2000 | 947 | 0.060 |
Why?
|
| Contact Lenses, Extended-Wear | 1 | 1985 | 6 | 0.060 |
Why?
|
| Urticaria | 1 | 2005 | 20 | 0.060 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 1985 | 22 | 0.060 |
Why?
|
| Nerve Compression Syndromes | 4 | 2000 | 22 | 0.060 |
Why?
|
| Cold Temperature | 1 | 2005 | 78 | 0.060 |
Why?
|
| Blindness | 3 | 2000 | 71 | 0.060 |
Why?
|
| Diplopia | 3 | 2002 | 39 | 0.060 |
Why?
|
| Keratitis | 1 | 1985 | 116 | 0.060 |
Why?
|
| Macular Degeneration | 1 | 1985 | 115 | 0.060 |
Why?
|
| Kentucky | 1 | 2023 | 28 | 0.060 |
Why?
|
| Tennessee | 1 | 2023 | 27 | 0.060 |
Why?
|
| Cherubism | 1 | 2003 | 1 | 0.050 |
Why?
|
| Remote Consultation | 1 | 2023 | 24 | 0.050 |
Why?
|
| Ciliary Body | 1 | 1983 | 31 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2000 | 56 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 705 | 0.050 |
Why?
|
| Quality Control | 1 | 2023 | 121 | 0.050 |
Why?
|
| Granuloma, Giant Cell | 1 | 2003 | 13 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2022 | 6173 | 0.050 |
Why?
|
| Myxoma | 1 | 1983 | 29 | 0.050 |
Why?
|
| Patient Care | 2 | 2020 | 100 | 0.050 |
Why?
|
| Iris | 1 | 1983 | 65 | 0.050 |
Why?
|
| Debridement | 2 | 2001 | 89 | 0.050 |
Why?
|
| Uveal Neoplasms | 1 | 1983 | 59 | 0.050 |
Why?
|
| Epidermal Growth Factor | 2 | 2000 | 123 | 0.050 |
Why?
|
| Bites and Stings | 1 | 2002 | 29 | 0.050 |
Why?
|
| Phlebitis | 1 | 1982 | 2 | 0.050 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2003 | 27 | 0.050 |
Why?
|
| Professional Misconduct | 1 | 2022 | 35 | 0.050 |
Why?
|
| Retinal Artery | 1 | 1982 | 16 | 0.050 |
Why?
|
| Tears | 1 | 2004 | 172 | 0.050 |
Why?
|
| Retinal Vein | 1 | 1982 | 12 | 0.050 |
Why?
|
| Health Facilities | 1 | 2023 | 61 | 0.050 |
Why?
|
| Emphysema | 2 | 1994 | 67 | 0.050 |
Why?
|
| Social Responsibility | 1 | 2002 | 80 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 1985 | 308 | 0.050 |
Why?
|
| Encephalocele | 2 | 1993 | 51 | 0.050 |
Why?
|
| Adenoma | 1 | 1983 | 128 | 0.050 |
Why?
|
| Intercostal Nerves | 1 | 2022 | 8 | 0.050 |
Why?
|
| Ossification, Heterotopic | 1 | 1982 | 41 | 0.050 |
Why?
|
| Epigastric Arteries | 1 | 2022 | 7 | 0.050 |
Why?
|
| Monitoring, Intraoperative | 1 | 2003 | 133 | 0.050 |
Why?
|
| Choroid | 1 | 1982 | 39 | 0.050 |
Why?
|
| Embolism | 1 | 1982 | 47 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 2434 | 0.050 |
Why?
|
| Ichthyosis, Lamellar | 1 | 2001 | 8 | 0.050 |
Why?
|
| Tolosa-Hunt Syndrome | 1 | 2001 | 4 | 0.050 |
Why?
|
| Fibroblasts | 3 | 2000 | 889 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 1998 | 1249 | 0.050 |
Why?
|
| Sensation | 1 | 2022 | 57 | 0.050 |
Why?
|
| Bone Remodeling | 2 | 1999 | 54 | 0.050 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 1999 | 43 | 0.050 |
Why?
|
| Dogs | 1 | 2002 | 775 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2001 | 89 | 0.050 |
Why?
|
| Clarithromycin | 2 | 1999 | 127 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 513 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 61 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2001 | 158 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 78 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2021 | 347 | 0.040 |
Why?
|
| Prosthesis Implantation | 2 | 2000 | 142 | 0.040 |
Why?
|
| Growth Substances | 1 | 2000 | 113 | 0.040 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2000 | 7 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 174 | 0.040 |
Why?
|
| Prognosis | 2 | 2020 | 4700 | 0.040 |
Why?
|
| Ethmoid Bone | 1 | 2000 | 9 | 0.040 |
Why?
|
| Epinephrine | 1 | 2021 | 180 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2001 | 626 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 334 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2000 | 189 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2020 | 349 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2000 | 667 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 572 | 0.040 |
Why?
|
| Software | 1 | 2023 | 687 | 0.040 |
Why?
|
| Rabbits | 4 | 2000 | 718 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 219 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 458 | 0.040 |
Why?
|
| Poverty | 1 | 2022 | 425 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2012 | 315 | 0.040 |
Why?
|
| Motivation | 1 | 2020 | 319 | 0.040 |
Why?
|
| Eyelashes | 1 | 1997 | 3 | 0.040 |
Why?
|
| Biocompatible Materials | 1 | 1998 | 119 | 0.040 |
Why?
|
| Headache | 1 | 1998 | 107 | 0.040 |
Why?
|
| Dry Eye Syndromes | 1 | 2001 | 267 | 0.040 |
Why?
|
| Hair Diseases | 1 | 1997 | 14 | 0.040 |
Why?
|
| Pain | 1 | 2021 | 451 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 586 | 0.040 |
Why?
|
| Foreign-Body Reaction | 1 | 1997 | 15 | 0.040 |
Why?
|
| Logistic Models | 1 | 2002 | 1817 | 0.040 |
Why?
|
| Eye Injuries, Penetrating | 2 | 1995 | 19 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 1998 | 110 | 0.030 |
Why?
|
| Mitomycin | 1 | 1997 | 49 | 0.030 |
Why?
|
| Child | 11 | 2008 | 24605 | 0.030 |
Why?
|
| Retrobulbar Hemorrhage | 1 | 1996 | 1 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 447 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 651 | 0.030 |
Why?
|
| Nose Deformities, Acquired | 1 | 1996 | 12 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2012 | 684 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1279 | 0.030 |
Why?
|
| Injections | 3 | 2006 | 155 | 0.030 |
Why?
|
| Porosity | 3 | 2000 | 36 | 0.030 |
Why?
|
| Corneal Transplantation | 1 | 1996 | 49 | 0.030 |
Why?
|
| Mycoses | 1 | 1997 | 118 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 128 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 962 | 0.030 |
Why?
|
| Nose | 1 | 1997 | 94 | 0.030 |
Why?
|
| Prednisone | 2 | 1994 | 278 | 0.030 |
Why?
|
| Temporomandibular Joint Dysfunction Syndrome | 1 | 1995 | 2 | 0.030 |
Why?
|
| Rhinoplasty | 1 | 1996 | 44 | 0.030 |
Why?
|
| Mucocele | 2 | 1995 | 9 | 0.030 |
Why?
|
| Orbital Pseudotumor | 1 | 1995 | 10 | 0.030 |
Why?
|
| Mycobacterium chelonae | 1 | 1995 | 6 | 0.030 |
Why?
|
| Epithelium | 2 | 1989 | 364 | 0.030 |
Why?
|
| Hypersensitivity | 1 | 1997 | 185 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2014 | 249 | 0.030 |
Why?
|
| Hydrocephalus | 1 | 2018 | 245 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 1998 | 684 | 0.030 |
Why?
|
| Cushing Syndrome | 1 | 1994 | 16 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1995 | 208 | 0.030 |
Why?
|
| Contraindications | 1 | 1994 | 78 | 0.030 |
Why?
|
| Pigment Epithelium of Eye | 2 | 1985 | 37 | 0.030 |
Why?
|
| Melanocytes | 2 | 1992 | 48 | 0.030 |
Why?
|
| Substance Abuse Detection | 1 | 1994 | 42 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 427 | 0.030 |
Why?
|
| Limbus Corneae | 1 | 1993 | 33 | 0.030 |
Why?
|
| Eye Foreign Bodies | 1 | 1993 | 15 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 9119 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1993 | 259 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1993 | 75 | 0.030 |
Why?
|
| Parotid Diseases | 1 | 1992 | 2 | 0.030 |
Why?
|
| Prolapse | 1 | 1992 | 11 | 0.030 |
Why?
|
| Meningocele | 1 | 1993 | 19 | 0.030 |
Why?
|
| Plastics | 1 | 1992 | 13 | 0.030 |
Why?
|
| Maxillary Diseases | 1 | 1992 | 3 | 0.030 |
Why?
|
| Infant | 6 | 2008 | 12594 | 0.030 |
Why?
|
| Reoperation | 2 | 1997 | 834 | 0.020 |
Why?
|
| Vision Disorders | 4 | 1998 | 211 | 0.020 |
Why?
|
| Hyperbaric Oxygenation | 1 | 1992 | 22 | 0.020 |
Why?
|
| Gluconates | 1 | 2012 | 6 | 0.020 |
Why?
|
| Mucormycosis | 1 | 1992 | 27 | 0.020 |
Why?
|
| Connective Tissue Diseases | 1 | 1992 | 30 | 0.020 |
Why?
|
| Nevus, Pigmented | 1 | 1992 | 32 | 0.020 |
Why?
|
| Hemifacial Spasm | 1 | 2012 | 17 | 0.020 |
Why?
|
| Polymers | 1 | 1992 | 104 | 0.020 |
Why?
|
| Cerebellar Diseases | 1 | 1992 | 74 | 0.020 |
Why?
|
| Papilloma | 1 | 1991 | 26 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 1568 | 0.020 |
Why?
|
| Dacryocystitis | 1 | 1991 | 20 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 1992 | 141 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1992 | 225 | 0.020 |
Why?
|
| Cilia | 1 | 1991 | 73 | 0.020 |
Why?
|
| Histiocytosis | 1 | 1991 | 19 | 0.020 |
Why?
|
| Craniofacial Dysostosis | 1 | 1991 | 19 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 1991 | 43 | 0.020 |
Why?
|
| Facial Nerve | 1 | 1990 | 25 | 0.020 |
Why?
|
| Nasolacrimal Duct | 2 | 1991 | 22 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1701 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 1175 | 0.020 |
Why?
|
| Cell Count | 2 | 2000 | 254 | 0.020 |
Why?
|
| Tetracycline | 1 | 1990 | 76 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 1991 | 79 | 0.020 |
Why?
|
| Bone and Bones | 1 | 1991 | 267 | 0.020 |
Why?
|
| Graves Disease | 1 | 1989 | 16 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1992 | 300 | 0.020 |
Why?
|
| Administration, Topical | 2 | 2006 | 139 | 0.020 |
Why?
|
| Bone Density | 1 | 1991 | 319 | 0.020 |
Why?
|
| Myositis | 1 | 1989 | 62 | 0.020 |
Why?
|
| Nervous System Neoplasms | 1 | 1988 | 12 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2012 | 471 | 0.020 |
Why?
|
| Methods | 1 | 1988 | 149 | 0.020 |
Why?
|
| Endophthalmitis | 2 | 1993 | 77 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1398 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 1989 | 168 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 1988 | 194 | 0.020 |
Why?
|
| Dystonia | 1 | 1989 | 171 | 0.020 |
Why?
|
| Mouth | 1 | 1988 | 62 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 1987 | 20 | 0.020 |
Why?
|
| Medical Illustration | 1 | 1986 | 18 | 0.020 |
Why?
|
| Muscle Spasticity | 1 | 1987 | 73 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2007 | 95 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1986 | 37 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 1987 | 245 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 1991 | 960 | 0.020 |
Why?
|
| Osteochondrodysplasias | 1 | 1986 | 66 | 0.020 |
Why?
|
| Macula Lutea | 1 | 1985 | 45 | 0.020 |
Why?
|
| Cellulitis | 1 | 2005 | 62 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1993 | 1536 | 0.010 |
Why?
|
| Cosmetic Techniques | 1 | 2004 | 11 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 2004 | 49 | 0.010 |
Why?
|
| Facial Hemiatrophy | 1 | 2003 | 3 | 0.010 |
Why?
|
| Chondroitin | 1 | 1983 | 3 | 0.010 |
Why?
|
| Visual Fields | 2 | 1998 | 133 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1983 | 100 | 0.010 |
Why?
|
| Stents | 1 | 1989 | 889 | 0.010 |
Why?
|
| Euthanasia, Animal | 1 | 2002 | 2 | 0.010 |
Why?
|
| Face | 1 | 2004 | 179 | 0.010 |
Why?
|
| Pigmentation Disorders | 1 | 1982 | 23 | 0.010 |
Why?
|
| Hyperparathyroidism | 1 | 1982 | 24 | 0.010 |
Why?
|
| Animals | 5 | 2002 | 34392 | 0.010 |
Why?
|
| Hernia | 1 | 2002 | 19 | 0.010 |
Why?
|
| Pupil | 1 | 1982 | 71 | 0.010 |
Why?
|
| Ophthalmoplegia | 1 | 2002 | 54 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 824 | 0.010 |
Why?
|
| Corneal Diseases | 1 | 1982 | 100 | 0.010 |
Why?
|
| Herniorrhaphy | 1 | 2002 | 82 | 0.010 |
Why?
|
| Postoperative Period | 2 | 1993 | 335 | 0.010 |
Why?
|
| Calcinosis | 1 | 1982 | 179 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2000 | 27 | 0.010 |
Why?
|
| Aggression | 1 | 2002 | 223 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2002 | 490 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1986 | 548 | 0.010 |
Why?
|
| Retina | 1 | 1982 | 450 | 0.010 |
Why?
|
| Entropion | 1 | 1998 | 2 | 0.010 |
Why?
|
| Amblyopia | 1 | 1998 | 31 | 0.010 |
Why?
|
| Blepharophimosis | 1 | 1998 | 26 | 0.010 |
Why?
|
| Forearm | 1 | 1998 | 45 | 0.010 |
Why?
|
| Tibia | 1 | 1998 | 70 | 0.010 |
Why?
|
| Aspergillus flavus | 1 | 1997 | 2 | 0.010 |
Why?
|
| Mitosporic Fungi | 1 | 1997 | 9 | 0.010 |
Why?
|
| Itraconazole | 1 | 1997 | 25 | 0.010 |
Why?
|
| Paranasal Sinuses | 1 | 1997 | 19 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2000 | 467 | 0.010 |
Why?
|
| Migraine Disorders | 1 | 1998 | 63 | 0.010 |
Why?
|
| Evoked Potentials, Visual | 1 | 1997 | 35 | 0.010 |
Why?
|
| Sphenoid Sinus | 1 | 1997 | 12 | 0.010 |
Why?
|
| Turbinates | 1 | 1997 | 12 | 0.010 |
Why?
|
| Endoscopes | 1 | 1997 | 20 | 0.010 |
Why?
|
| Pedigree | 2 | 1991 | 1609 | 0.010 |
Why?
|
| Electrocoagulation | 1 | 1997 | 36 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1982 | 562 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 1410 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2003 | 735 | 0.010 |
Why?
|
| Skull Fractures | 1 | 1997 | 43 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1997 | 154 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 300 | 0.010 |
Why?
|
| Cicatrix | 1 | 1996 | 124 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 1997 | 291 | 0.010 |
Why?
|
| Addison Disease | 1 | 1994 | 1 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1995 | 230 | 0.010 |
Why?
|
| Remission Induction | 1 | 1995 | 301 | 0.010 |
Why?
|
| Fistula | 1 | 1995 | 49 | 0.010 |
Why?
|
| Self Medication | 1 | 1994 | 23 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 1982 | 881 | 0.010 |
Why?
|
| Tendons | 1 | 1993 | 41 | 0.010 |
Why?
|
| Dissection | 1 | 1993 | 54 | 0.010 |
Why?
|
| Periosteum | 1 | 1993 | 33 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1996 | 546 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1992 | 90 | 0.010 |
Why?
|
| Vision, Ocular | 1 | 1993 | 122 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1995 | 470 | 0.010 |
Why?
|
| Hearing Disorders | 1 | 1991 | 27 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1991 | 31 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1991 | 62 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1995 | 1201 | 0.010 |
Why?
|
| Intelligence | 1 | 1991 | 102 | 0.010 |
Why?
|
| Algorithms | 1 | 1996 | 1634 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1990 | 245 | 0.000 |
Why?
|
| Prednisolone | 1 | 1988 | 74 | 0.000 |
Why?
|
| Pia Mater | 1 | 1986 | 10 | 0.000 |
Why?
|
| Arachnoid | 1 | 1986 | 8 | 0.000 |
Why?
|
| Membranes | 1 | 1982 | 23 | 0.000 |
Why?
|
| Iris Diseases | 1 | 1982 | 15 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1982 | 154 | 0.000 |
Why?
|
| Glaucoma | 1 | 1982 | 87 | 0.000 |
Why?
|